Kaplan & Sadock’s Pocket Handbook of Psychiatric Drug Treatment

447 Pages·2018·2.41 MB·English

by  Benjamin Sadock

C E
ONSULTING DITOR
S A , M.D.
AMOON HMAD
Associate Professor and Attending Physician
Department of Psychiatry
NYU School of Medicine
New York, New York
KAPLAN & SADOCK’S
POCKET HANDBOOK
OF PSYCHIATRIC
DRUG TREATMENT
Seventh Edition
B J. S , M.D.
ENJAMIN ADOCK
Menas S. Gregory Professor of Psychiatry Department of Psychiatry, New York University School of
Medicine Attending Psychiatrist, Tisch Hospital Attending Psychiatrist, Bellevue Hospital Center New
York, New York
N S , M.D.
ORMAN USSMAN
Professor of Psychiatry, Department of Psychiatry New York University School of Medicine New York,
New York
V A. S , M.D.
IRGINIA ADOCK
Professor of Psychiatry, Department of Psychiatry New York University School of Medicine Attending
Psychiatrist, Tisch Hospital Attending Psychiatrist, Bellevue Hospital Center New York, New York
Acquisitions Editor: Chris Teja
Development Editor: Ashley Fischer
Editorial Coordinator: Alexis Pozonsky Marketing Manager: Rachel Mante-Leung
Production Project Manager: Bridgett Dougherty Design Coordinator: Teresa Mallon
Manufacturing Coordinator: Beth Welsh Prepress Vendor: Aptara, Inc.
7th edition
Copyright © 2019 Wolters Kluwer.
© 2014 by LIPPINCOTT WILLIAMS & WILKINS, a WOLTERS KLUWER business ©
2011, 2006, 2001 by LIPPINCOTT WILLIAMS & WILKINS
All rights reserved. This book is protected by copyright. No part of this book may be reproduced or
transmitted in any form or by any means, including as photocopies or scanned-in or other electronic copies,
or utilized by any information storage and retrieval system without written permission from the copyright
owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this
book prepared by individuals as part of their official duties as U.S. government employees are not covered
by the above-mentioned copyright. To request permission, please contact Wolters Kluwer at Two
Commerce Square, 2001 Market Street, Philadelphia, PA 19103, via email at [email protected], or via
our website at lww.com (products and services).
9 8 7 6 5 4 3 2 1
Printed in China
Library of Congress Cataloging-in-Publication Data Names: Sadock, Benjamin J., 1933-author. |
Sussman, Norman, author. | Sadock, Virginia A., author.
Title: Kaplan & Sadock’s pocket handbook of psychiatric drug treatment / Benjamin J.
Sadock, Norman Sussman, Virginia A. Sadock.
Other titles: Kaplan and Sadock’s pocket handbook of psychiatric drug treatment | Pocket
handbook of psychiatric drug treatment Description: Seventh edition. | Philadelphia :
Wolters Kluwer, [2019] | Includes bibliographical references and index.
Identifiers: LCCN 2017055311 | ISBN 9781496389602
Subjects: | MESH: Mental Disorders–drug therapy | Psychotropic Drugs–therapeutic use |
Handbooks Classification: LCC RC483 | NLM WM 34 | DDC 616.89/18—dc23 LC
record available at https://lccn.loc.gov/2017055311
This work is provided “as is,” and the publisher disclaims any and all warranties, express or implied,
including any warranties as to accuracy, comprehensiveness, or currency of the content of this work.
This work is no substitute for individual patient assessment based upon healthcare professionals’
examination of each patient and consideration of, among other things, age, weight, gender, current or prior
medical conditions, medication history, laboratory data and other factors unique to the patient. The
publisher does not provide medical advice or guidance and this work is merely a reference tool. Healthcare
professionals, and not the publisher, are solely responsible for the use of this work including all medical
judgments and for any resulting diagnosis and treatments.
Given continuous, rapid advances in medical science and health information, independent professional
verification of medical diagnoses, indications, appropriate pharmaceutical selections and dosages, and
treatment options should be made and healthcare professionals should consult a variety of sources. When
prescribing medication, healthcare professionals are advised to consult the product information sheet (the
manufacturer’s package insert) accompanying each drug to verify, among other things, conditions of use,
warnings and side effects and identify any changes in dosage schedule or contraindications, particularly if
the medication to be administered is new, infrequently used or has a narrow therapeutic range. To the
maximum extent permitted under applicable law, no responsibility is assumed by the publisher for any
injury and/or damage to persons or property, as a matter of products liability, negligence law or otherwise,
or from any reference to or use by any person of this work.
LWW.com
Dedicated
to our children
James and Victoria
and to our grandchildren
Celia, Emily, Oliver, and Joel
B.J.S.
V.A.S.
Dedicated
to my wife Susan
and my children
Rebecca and Zachary
N.S.
Preface
This is the seventh edition of Kaplan & Sadock’s Pocket Handbook of
Psychiatric Drug Treatment, the first of which was published almost 25 years
ago. During that time, a revolution in the treatment of mental illness occurred,
sparked by the introduction of psychotropic drugs. This book has kept up with
that revolution and contains information about every drug used in the treatment
of mental illness. It has served the needs of many professionals who provide care
for the mentally ill—psychiatrists and nonpsychiatric physicians, psychiatric
residents, medical students, clinical psychologists, psychiatric nurses, and others.
GOALS OF THIS BOOK
This book covers the entire spectrum of psychiatric drug therapy used in the
clinical practice of psychiatry. As with each new edition, every section has been
updated and revised and new sections added. Many drugs approved by the FDA
as treatments for psychiatric disorders have been found to have benefits beyond
those recognized at the time of their initial marketing, thus expanding the range
of disorders that can be treated. Some have also been found to have
unanticipated risks. These developments serve to emphasize the importance of
having updated information about drug selection and use that reflects both
research data and clinical experience. The goals of this book are to present this
information clearly and concisely.
ORGANIZATION OF THIS BOOK
Following the format of previous editions, whenever possible, we classify drugs
according to their pharmacological activity and mechanism of action rather than
using such categories as antidepressants, antipsychotics, anxiolytics, and mood
stabilizers which are overly broad. For example, many antidepressant drugs are
used to treat anxiety disorders; some anxiolytics are used to treat depression and
bipolar disorders; and drugs from all categories are used to treat other conditions
such as eating disorders and impulse control disorders to name but two. This
organization is used in textbooks of pharmacology and we believe
psychopharmacology should follow that organization as much as possible, given
the current state of our knowledge.
HOW TO USE THIS BOOK
At the beginning of the book, the reader will find a chart (Table A) that lists each
and every drug and the chapter in which it is found. In addition, the index lists
each drug separately under its generic and brand name and the page number on
which it can be found. Each section provides a wealth of data that includes (1)
the drug’s chemical name; (2) preparation and dosages; (3) pharmacologic
actions including its pharmacokinetics and pharmacodynamics; (4) the
indications for use and clinical applications; (5) use in children, elderly persons,
and pregnant and nursing women; (6) side effects and adverse and allergic
reactions; and (7) drug–drug interactions.
NUTRITIONAL SUPPLEMENTS
We continue to include an updated chapter covering nutritional supplements as
well as herb and plant preparations with psychoactive properties because their
use is increasing. Many persons medicate themselves with these compounds and
while some may be beneficial, no standards of use have been developed;
however, many are being evaluated under the auspices of the National Center for
Complementary and Alternative Medicine (NCCAM). Clinicians must be alert to
the possibility of adverse effects of these agents in addition to their interactions
with prescribed psychotropic medications.
DRUGS USED IN THE TREATMENT OF OBESITY
We include a chapter on drugs used to treat obesity for two reasons: Many
psychotropic drugs influence metabolism in such a way that significant weight
gain occurs as a side effect; and obesity, now classified as a disease by the
American Medical Association, occurs in conjunction with many psychiatric
disorders and psychiatrists have a role to play in its management.
MEDICATION-INDUCED MOVEMENT DISORDERS
Movement disorders are commonly associated with the use of potent
psychotropic medications and for that reason a special chapter has been devoted
to this topic. Some movement disorders, such as neuroleptic-induced tardive
dyskinesia can be potentially disabling and others such as neuroleptic malignant
syndrome can be life threatening. Psychiatrists must know which drugs are
associated with these effects and must remain vigilant when these drugs are
prescribed. This new section will be very helpful to clinicians in this regard.